TScan Therapeutics (NASDAQ:TCRX) Cut to Neutral at HC Wainwright

HC Wainwright cut shares of TScan Therapeutics (NASDAQ:TCRX) from a buy rating to a neutral rating in a research report report published on Tuesday morning, MarketBeat Ratings reports. They currently have $1.00 target price on the stock. HC Wainwright also issued estimates for TScan Therapeutics’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at ($0.24) EPS.

Several other research firms have also weighed in on TCRX. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Lifesci Capital lowered TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Wednesday, September 2nd. Finally, Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.67.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $0.32 on Tuesday. The firm has a fifty day moving average of $0.78 and a two-hundred day moving average of $0.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. The stock has a market capitalization of $21.55 million, a price-to-earnings ratio of -0.35 and a beta of 1.07. TScan Therapeutics has a 52 week low of $0.31 and a 52 week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%.The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. As a group, equities research analysts predict that TScan Therapeutics will post -1.04 EPS for the current year.

Institutional Trading of TScan Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in shares of TScan Therapeutics during the second quarter worth about $48,000. BlackRock Inc. bought a new position in shares of TScan Therapeutics during the 2nd quarter valued at about $975,000. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at approximately $25,000. HRT Financial LP acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at approximately $26,000. Finally, Boothbay Fund Management LLC increased its stake in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.